Intersect ENT
$20.199876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$20.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.04 (+0.20%) Today
$0.00 (0.00%) As of 9:07 PM UTC after-hours
Why Robinhood?
You can buy or sell Intersect ENT and other stocks, options, and ETFs commission-free!
About XENT
Intersect ENT, Inc. Common Stock, also called Intersect ENT, is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA. The listed name for XENT is Intersect ENT, Inc. Common Stock.
CEO
Thomas A. West
Employees
402
Headquarters
Menlo Park, California
Founded
2003
Market Cap
660.60M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
316.31K
High Today
$20.31
Low Today
$19.76
Open Price
$19.76
Volume
156.96K
52 Week High
$31.46
52 Week Low
$5.97
Collections
Analyst Ratings
30%
of 10 ratings
Buy
30%
Hold
60%
Sell
10%
XENT Earnings
-$0.65
-$0.43
-$0.22
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 22, Pre-Market